Scoping review of biosimilar disease-modifying antirheumatic drugs in pregnancy: evidence gaps and proposed outcome reporting framework
Rheumatol Int. 2025 Sep 29;45(10):241. doi: 10.1007/s00296-025-05968-3. ABSTRACT Biologic disease-modifying antirheumatic drugs (DMARDs) have revolutionized the management of autoimmune diseases. Biosimilar DMARDs have emerged as …